Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

This study will use dual energy x-ray computed tomography (DECT) to evaluate the relationship between heterogeneous perfusion, hypoxia (low oxygen in inspired gas) and induction of pulmonary vascular dilatation to characterize emphysema susceptibility in a normal smoking population. The investigators will correlate DECT measures of perfusion with lung injury measured by single photon emission computed tomography (SPECT). The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema

Study Overview

• Status: Recruiting
• Conditions: Emphysema
• Intervention / Treatment: Drug: Hypoxia administration study group; Drug: Hyperoxia administration study group; Drug: Sildenafil

Detailed Description

Imaging-based metrics have recently played a central role in the quest to identify chronic obstructive pulmonary disease (COPD) phenotypes, serving to establish homogeneous sub-populations to aid in genotyping, therapeutic targeting and design and outcomes assessment. Recent findings in both animals and humans have lead us to believe that CT derived perfusion (PBF) and mean transit time (MTT) measures within regionally injured lung parenchyma provide for a functional phenotype of which may be directly tied to the etiology of the pathologic process leading to emphysema in acentrilobular emphysema susceptible subset of the smoking population. The primary hypotheses of the proposal are built around the notion that smokers prone to emphysema have abnormal vasoregulation in that regional hypoxic pulmonary vasoconstriction (HPV) continues despite regional lung injury. This failure to block vasoconstriction alters the repair response and leads to tissue destruction in emphysema susceptible smokers (SS) with abnormal vasoregulation. The normal response to regional hypoxia is to shunt blood towards better-ventilated regions. However, smoking induces small scale, regional infiltrates which in turn lead to local hypoxia, HPV would interfere with defense mechanisms serving to clear the irritant and thus interfere with mechanisms of repair. The investigators have demonstrated that, in SS subjects with normal PFTs but CT evidence of early centriacinar emphysema (CAE), there is an increased heterogeneity of perfusion. This is supportive of the notion that attenuation of vasoconstriction has failed. Further, the investigators have demonstrated a tight correlation between quantitative CT evidence of emphysema with reduced lung volume (LV) filling down to very small amounts of emphysema.

The investigators outline a series of experiments seeking to:

1. link increased pulmonary perfusion heterogeneity in SS subjects to the lung's response to alveolar oxygenation;
2. establish that the perfusion heterogeneity is reversible;
3. demonstrate that the response to inflammation and not just inflammation itself is a key factor in the increased heterogeneity.

With any combination of positive outcomes of this study, the investigators will have provided new insights into disease etiology, serving to provide new targets for disease intervention and providing the tools needed for assessing outcomes.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Debra J OConnell Moore, MBA; Phone Number: 319-356-1693; Email: debra-oconnell-moore@uiowa.edu
• Study Contact Backup: Name: Sue E Salisbury, BS; Phone Number: 319-356-1810; Email: sue-salisbury@uiowa.edu

Study Locations

• United States
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Recruiting
      • University of Iowa
      • Contact: Debra O'Connell-Moore, BS; Phone Number: 319-356-1785; Email: debra-oconnell-moore@uiowa.edu
      • Contact: Ann Thompson; Phone Number: 319-353-6213; Email: ann-thompson@uiowa.edu
      • Principal Investigator: Eric A Hoffman, Ph.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Must be between the ages of 25 and 65.
2. Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level).

3. Must have pulmonary function test (PFT) results that meet the following (there will be two groups):

   Group 1:

   • Forced expiratory volume at one second (FEV1)/Forced vital capacity (FVC) > 70%
   • Forced Expiratory Flow at 25-75% of predicted(FEF25-75) > 79% of predicted
   • FVC greater than 80% of predicted

   Group 2:

   For subjects with mild lung impairment:

   • FEV1>80% of predicted
   • FEV1/FVC<0.7
4. Must be able to give informed consent for self.

Exclusion Criteria:

1. Pregnant or breastfeeding females.
2. Body Mass Index (BMI) greater than 32.
3. Weight of greater than 220 pounds (100 kg).
4. Allergies to shell fish, seafood, eggs or iodine.
5. Heart disease, kidney disease or diabetes.
6. Diagnosis of asthma.
7. Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed).
8. Any metal in or on the body between the nose and the abdomen.
9. Any major organ system disease (by judgment of study medical team).
10. A glomerular filtration rate of 60 cc per minute or less.

For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows:

1. Nitroglycerin usage or nitrates (in addition to nitroglycerin) and use of phosphodiesterase 5 (PDE5) inhibitors within the previous 7 days of the study date.
2. Prior history of hypersensitivity to Sildenafil.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Hypoxia Administration study group; 40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.	Drug: Hypoxia administration study group; scan completed after 5 minutes of breathing in hypoxic air; Other Names: Oxygen
Experimental: Hyperoxia Administration study group; 40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.	Drug: Hyperoxia administration study group; scan completed after up to 15 minutes of breathing in hyperoxic air; Other Names: Oxygen
Experimental: Sildenafil; 40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.	Drug: Sildenafil; One dose of 20 mg Sildenafil will be given one hour before CT imaging.; Other Names: Revatio

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Perfused blood volume assessed pre and post sildenafil administration	Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post the administration of sildenafil.	Pre sildenafil adminstration and one hour after sildenafil adminstration.
Perfused blood volume assessed pre and post hyperoxic breathing	Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post hyperoxic breathing	Pre hyperoxic breathing and 15 minutes post hyperoxic breathing
Perfused blood volume assessed pre and post hypoxic breathing	Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post hypoxic breathing	Pre hypoxic breathing and 15 minutes post hypoxic breathing

Collaborators and Investigators

• Sponsor: Eric A. Hoffman
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
• Investigators: Principal Investigator: Eric A Hoffman, PhD, University of Iowa

Publications and helpful links

General Publications

• Alford SK, van Beek EJ, McLennan G, Hoffman EA. Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7485-90. doi: 10.1073/pnas.0913880107. Epub 2010 Apr 5.
• Iyer KS, Newell JD Jr, Jin D, Fuld MK, Saha PK, Hansdottir S, Hoffman EA. Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. Am J Respir Crit Care Med. 2016 Mar 15;193(6):652-61. doi: 10.1164/rccm.201506-1196OC.

Study record dates

Study Major Dates

• Study Start (Actual): July 10, 2017
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: January 12, 2016
• First Submitted That Met QC Criteria: February 10, 2016
• First Posted (Estimated): February 15, 2016

Study Record Updates

• Last Update Posted (Actual): March 28, 2024
• Last Update Submitted That Met QC Criteria: March 27, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Chronic Disease; Pulmonary Emphysema; Emphysema; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Urological Agents; Enzyme Inhibitors; Phosphodiesterase Inhibitors; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate
• Other Study ID Numbers: 201508782; R01HL130883 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: CT images will be shared including non-contrast images at TLC, FRC and RV as well as dual energy CT image data used to assess regional perfused blood volume. All associated pulmonary function test results will be shared. CT-derived metrics
• IPD Sharing Time Frame: Data will be made available starting 6 months after publication of the primary results of each aim.
• IPD Sharing Access Criteria: Data will be provided to academic-based researchers upon written request to the PI, Eric A. Hoffman, PhD. A nominal charge will be made for the time it takes for a technician to prepare and transfer the requested data. This costs will not exceed $250. This service will be available for a minimum of 2 years of study close.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF

Study Data/Documents

1. Individual Participant Data Set
   Information identifier: Data Distribution

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No